Sign In
Buy PFE
$26.04
+0.350 (+1.36%)
At Close: Jun 05, 2026
UK regulator approves Pfizer's hair loss drug
07:39am, Wednesday, 01'st Nov 2023
Britain's medicines regulator on Wednesday approved Pfizer Inc's drug to treat hair loss caused by an autoimmune disease.
Pfizer Posted a Steep Loss. Is It Time to Sell?
06:19am, Wednesday, 01'st Nov 2023
Pfizer reported third-quarter results on Tuesday, Oct. 31. The company told investors it had to write down $5.6 billion worth of unused inventory in the third quarter.
Investor patience tested as pharmaceutical stocks take a tumble
06:07am, Wednesday, 01'st Nov 2023
The Health Care Select Sector SPDR Fund NYSEARCA: XLV was down 3.81% in the past month and 8.03% in the past three months. The latest round of pharmaceutical stock earnings isn't helping sector perfor
Unlike Pfizer, Moderna can meet 2023 COVID forecast, analysts say
06:03am, Wednesday, 01'st Nov 2023
Moderna should hit the lower end of its sales target for this year as it only needs to tap a small portion of the private market with its COVID vaccine to reach that goal, according to industry analys
Pfizer quarterly results hit by soft demand for COVID-19 products
08:20pm, Tuesday, 31'st Oct 2023
Sales of the company's coronavirus vaccine Comirnaty dropped 70% during the third quarter compared with the same period a year earlier, Pfizer reported on Tuesday.
We are keen to join forces with Seagan, says Pfizer CEO Albert Bourla
07:57pm, Tuesday, 31'st Oct 2023
Pfizer Chairman and CEO Albert Bourla joins 'Mad Money' host Jim Cramer to talk Q3 earnings results, partnering with Kansas City Chiefs Tight End Travis Kelce, acquiring BioHaven and more.
Pfizer CEO Albert Bourla talks Q3 earnings results with Jim Cramer
07:54pm, Tuesday, 31'st Oct 2023
Pfizer Chairman and CEO Albert Bourla joins 'Mad Money' host Jim Cramer to talk Q3 earnings results, partnering with Kansas City Chiefs Tight End Travis Kelce, acquiring BioHaven and more.
3 Top Dividend Stocks to Buy for Long-Term Growth
04:08pm, Tuesday, 31'st Oct 2023
When buying long-term dividend stocks, I would primarily look at three important factors. First, the amount of dividend payout and the dividend yield the blue-chip stock is delivering.
Pfizer to Sees No Major M&A Activity in 2024: CEO Bourla
03:30pm, Tuesday, 31'st Oct 2023
Pfizer Chairman and CEO Albert Bourla says the company is still in the market for acquisitions following its $43 billion acquisition of cancer biotech firm Seagen Inc., but 2024 will not see any major
Pfizer reports first quarterly loss since 2019
03:02pm, Tuesday, 31'st Oct 2023
Shares of Pfizer (PFE) slipped after the pharmaceutical company reported its first quarterly loss since 2019 in its third quarter earnings. Pfizer incurred a $5.5 billion non-cash write-off due to dec
Pfizer's (PFE) Q3 Loss Narrows, Sales Miss on COVID Slump
12:46pm, Tuesday, 31'st Oct 2023
Pfizer (PFE) reports mixed third-quarter 2023 results. It re-affirms its 2023 sales and earnings guidance provided earlier this month.
Markets Wait for Fed's FOMC Meeting Decisions
12:01pm, Tuesday, 31'st Oct 2023
Markets Wait for Fed's FOMC Meeting Decisions.
Pfizer Earnings Weighed Down Again by Dwindling COVID Sales
10:15am, Tuesday, 31'st Oct 2023
Unused stockpiles of COVID-19 treatment Paxlovid and muted demand for the same illness' vaccine weighed down on Pfizer's (PFE) third quarter earnings.
Pfizer's Coming for AbbVie's Market Share. Here's What It Means for Investors
10:07am, Tuesday, 31'st Oct 2023
Pfizer just got an approval for a drug to treat ulcerative colitis. AbbVie is still trying to consolidate its control over that market.
Pfizer (PFE) Reports Q3 Loss, Lags Revenue Estimates
09:47am, Tuesday, 31'st Oct 2023
Pfizer (PFE) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to earnings of $1.78 per share a year ago.
